Nykode prioritizes VB10.16, extends cash runway into 2029

Nykode Therapeutics ASA has unveiled an updated corporate strategy, prioritizing VB10.16 (now named abipapogene suvaplasmid or abi-suva) as its lead clinical asset. This DNA-based cancer vaccine, targeting HPV16-positive cancers, will advance into a randomized, open-label, multicenter Phase 2 trial (Abili-T) for first-line recurrent/metastatic head and neck cancer (1L r/m HNSCC), evaluating it in combination with pembrolizumab. The first interim efficacy analysis for this trial is anticipated in 2027.

The strategy also streamlines VB10.NEO development with targeted investments, aiming to position it as a leading individualized neoantigen therapy, and accelerates the antigen-specific immune tolerance (ASIT) platform, seeking partnerships for both.

Through disciplined execution and capital allocation, Nykode expects its cash runway to extend into 2029, or 2028 if a pending tax case is ruled against the company. As of June 30, 2025, Nykode reported a strong cash position of $70.0m, excluding a $32.2m non-current receivable related to the tax case. The company also plans to strengthen its Board with new high-caliber members, including a new Chair, to be elected at the 2026 Annual General Meeting.